🇺🇸 tripterygium wilfordii in United States

27 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 5 reports (18.52%)
  2. Dermatitis — 3 reports (11.11%)
  3. Drug Eruption — 3 reports (11.11%)
  4. Drug Ineffective — 3 reports (11.11%)
  5. Pneumonia — 3 reports (11.11%)
  6. Drug Ineffective For Unapproved Indication — 2 reports (7.41%)
  7. Intentional Product Use Issue — 2 reports (7.41%)
  8. Nausea — 2 reports (7.41%)
  9. Proteinuria — 2 reports (7.41%)
  10. Renal Failure Acute — 2 reports (7.41%)

Source database →

Other Immunology approved in United States

Frequently asked questions

Is tripterygium wilfordii approved in United States?

tripterygium wilfordii does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for tripterygium wilfordii in United States?

Zhi-Hong Liu, M.D. is the originator. The local marketing authorisation holder may differ — check the official source linked above.